hackint0sh/temp-data huggingface dataset:
protocolSection identificationModule nctId: NCT06361251, orgStudyIdInfo id: CS5_10, briefTitle: Interventional, Monocentric, Double-blind Randomized Category 2b Study Evaluating the Evaluation of the Tolerance of Cyto-selective Difluoroethane-based Cryotherapy in the Treatment of Brown Spots (Solar and Senile Lentigines, Post -Inflammatory Hyperpigmentation (Pih)) on the Face, acronym: CS5_10, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-04, primaryCompletionDateStruct date: 2024-12, completionDateStruct date: 2024-12, studyFirstPostDateStruct date: 2024-04-11, lastUpdatePostDateStruct date: 2024-04-17, sponsorCollaboratorsModule leadSponsor name: Cryonove Pharma, class: INDUSTRY, collaborators name: Dermatech, descriptionModule briefSummary: The goal of this clinical trial is to compare the 2 different prototype of cytoselectivecryotherapy devices (name of the devices : CRYONOVE) use in brown spots on the face of subject from different ethnicities. The main questions it aims to answer are:* the tolerance of 2 prototypes of cyto-selective cryotherapy treatments* the performance of 2 prototypes of cyto-selective cryotherapy treatments Participants will be treated for each spots with a definied prototype during 6 treatment visits.Researchers will compare the tolerance and performance of the 3 prototypes., conditionsModule conditions: Lentigo, conditions: Solar Lentigo, conditions: Post Inflammatory Hyperpigmentation, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, interventionModelDescription: Proof of concept study concerning 2 prototypes of cyto-selective cryotherapy devices corresponding to a modified CE marked medical device (ref: 822-v1)., primaryPurpose: TREATMENT, maskingInfo masking: DOUBLE, maskingDescription: Double blind (participant and care provider), whoMasked: PARTICIPANT, whoMasked: INVESTIGATOR, enrollmentInfo count: 30, type: ESTIMATED, armsInterventionsModule interventions name: CRYONOVE (EC14_4osc), interventions name: CRYONOVE (EC05osc), outcomesModule primaryOutcomes measure: Tolerance, secondaryOutcomes measure: Performance (Acquisitions C-cube), eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 75 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: SMU - Photobiology Laboratory, Sefako Makgatho Health Sciences University, city: Pretoria, country: South Africa, geoPoint lat: -25.74486, lon: 28.18783, hasResults: False
protocolSection identificationModule nctId: NCT06361225, orgStudyIdInfo id: 0075-24-MMC, briefTitle: Routine Use of RUSH Protocol in the Intensive Care Unit, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-08-01, primaryCompletionDateStruct date: 2025-08-01, completionDateStruct date: 2025-08-01, studyFirstPostDateStruct date: 2024-04-11, lastUpdatePostDateStruct date: 2024-04-11, sponsorCollaboratorsModule leadSponsor name: Meir Medical Center, class: OTHER, descriptionModule briefSummary: The RUSH protocol has been used for several years for the rapid evaluation of a patient admitted to the emergency room with shock. Traditionally, its use was especially common in trauma victims, but later its use was extended to patients admitted to the emergency room with shock from any reason. The protocol includes rapid assessment with the guideness of ultrasound of heart contraction, assessment for pleural effusions, assessment of intra-abdominal blood (FAST), diagnosis of venous thrombosis (DVT), and rulling out hydronephrosis. It can also add a pupil size assessment and an evaluation of the gallbladder and bile ducts, as well as the size of the bladder. In intensive care, we use this protocol (or part of it) for the evaluation of a patient who is deteriorating in the ICU for an unknown reason . In some patients we use this protocol as a routine part of the physical examination as part of the daily patient evaluation.We would like to investigate whether the routine use of the RUSH protocol as part of the daily patient evaluation in the general intensive care unit will lead to any change in the patient's management., conditionsModule conditions: RUSH Protocol, designModule studyType: OBSERVATIONAL, designInfo observationalModel: CASE_ONLY, timePerspective: PROSPECTIVE, enrollmentInfo count: 50, type: ESTIMATED, armsInterventionsModule interventions name: evaluation with RUSH protocol, outcomesModule primaryOutcomes measure: Change of patient medical therapy, primaryOutcomes measure: Performing unplanned laboratory tests, primaryOutcomes measure: Performing unplanned image tests, primaryOutcomes measure: Performing unplanned invasive procedure, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 99 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Meir Medical Center, city: Kfar Saba, country: Israel, geoPoint lat: 32.175, lon: 34.90694, hasResults: False
protocolSection identificationModule nctId: NCT06361212, orgStudyIdInfo id: BJXH-2022-002, briefTitle: Ethoximod Pharmacokinetics In Healthy Subjects, statusModule overallStatus: COMPLETED, startDateStruct date: 2022-09-01, primaryCompletionDateStruct date: 2022-09-20, completionDateStruct date: 2024-01-12, studyFirstPostDateStruct date: 2024-04-11, lastUpdatePostDateStruct date: 2024-04-11, sponsorCollaboratorsModule leadSponsor name: Longevity Inc., class: INDUSTRY, descriptionModule briefSummary: The goal of this clinical trial is to evaluate the tolerability, pharmacokinetics and pharmacodynamics of Ethoximod in healthy subjects. The main questions it arms to answer are:1. to evaluate the safety and tolerance of Ethoximod in healthy subjects after single or repeated doses.2. to assess the pharmacokinetics and pharmacodynamics of Ethoximod in healthy subjects after single or repeated doses.3. to evaluate of the effect of food on the pharmacokinetics of Ethoximod in healthy subjects Participants will receive test tablets or placebo at the indicated date and collect blood samples., conditionsModule conditions: Psoriasis, designModule studyType: INTERVENTIONAL, phases: PHASE1, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: TREATMENT, maskingInfo masking: DOUBLE, whoMasked: PARTICIPANT, whoMasked: INVESTIGATOR, enrollmentInfo count: 65, type: ACTUAL, armsInterventionsModule interventions name: Ethoximod, outcomesModule primaryOutcomes measure: Peak plasma concentration (Cmax), primaryOutcomes measure: Time to peak plasma concentration (Tmax), primaryOutcomes measure: The lowest plasma concentration (Cmin), primaryOutcomes measure: Half-life (t1/2), primaryOutcomes measure: Number of adverse events and number of participants with adverse events, secondaryOutcomes measure: Lymphocyte count, secondaryOutcomes measure: Percentage of CD3+CD4+ and CD3+CD8+ T cells, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 50 Years, stdAges: ADULT, contactsLocationsModule locations facility: The first hospital of Jilin University, city: Changchun, state: Jilin, country: China, geoPoint lat: 43.88, lon: 125.32278, hasResults: False
protocolSection identificationModule nctId: NCT06361199, orgStudyIdInfo id: BJXH-2021-001, briefTitle: Proximod Pharmacokinetics in Healthy Subjects and Patients With Rheumatoid Arthritis, statusModule overallStatus: COMPLETED, startDateStruct date: 2021-12-16, primaryCompletionDateStruct date: 2022-02-16, completionDateStruct date: 2023-10-08, studyFirstPostDateStruct date: 2024-04-11, lastUpdatePostDateStruct date: 2024-04-19, sponsorCollaboratorsModule leadSponsor name: Longevity Inc., class: INDUSTRY, descriptionModule briefSummary: The goal of this clinical trial is to evaluate the tolerability, pharmacokinetics and pharmacodynamics of Proximod in healthy subjects and patients with rheumatoid arthritis. The main questions it arms to answer are:1. to evaluate the safety and tolerance of Proximod in health subjects after repeated doses.2. to assess the pharmacokinetics and pharmacodynamics of Proximod in healthy subjects after repeated doses.3. to evaluate the safety and tolerance of Proximod in patients with rheumatoid arthritis.4. to evaluate the pharmacokinetics and pharmacodynamics of Proximod in patients with rheumatoid arthritis.Participants will receive test tablets or placebo at the indicated date and collect blood samples., conditionsModule conditions: Rheumatoid Arthritis, designModule studyType: INTERVENTIONAL, phases: PHASE1, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: TREATMENT, maskingInfo masking: DOUBLE, whoMasked: PARTICIPANT, whoMasked: INVESTIGATOR, enrollmentInfo count: 22, type: ACTUAL, armsInterventionsModule interventions name: Proximod, interventions name: Placebo, outcomesModule primaryOutcomes measure: Peak plasma concentration (Cmax), primaryOutcomes measure: Time to peak plasma concentration (Tmax), primaryOutcomes measure: The lowest plasma concentration (Cmin), primaryOutcomes measure: Half-life (t1/2), primaryOutcomes measure: Area under the plasma concentration versus time curve (AUC), primaryOutcomes measure: Number of adverse events and number of participants with adverse events, secondaryOutcomes measure: Lymphocyte count, secondaryOutcomes measure: Percentage of CD3+CD4+ and CD3+CD8+T cells, secondaryOutcomes measure: ACR20 score in Patients With Rheumatoid Arthritis, secondaryOutcomes measure: Disease Activity Score（DAS28-CRP）in Patients With Rheumatoid Arthritis, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 70 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: The first hospital of Jilin University, city: Changchun, state: Jilin, country: China, geoPoint lat: 43.88, lon: 125.32278, hasResults: False
protocolSection identificationModule nctId: NCT06361186, orgStudyIdInfo id: BJXH-2017-001, briefTitle: Proximod Pharmacokinetics In Healthy Subjects, statusModule overallStatus: COMPLETED, startDateStruct date: 2017-09-14, primaryCompletionDateStruct date: 2017-11-01, completionDateStruct date: 2021-06-22, studyFirstPostDateStruct date: 2024-04-11, lastUpdatePostDateStruct date: 2024-04-11, sponsorCollaboratorsModule leadSponsor name: Longevity Inc., class: INDUSTRY, descriptionModule briefSummary: The goal of this clinical trial is to evaluate the tolerability, pharmacokinetics and pharmacodynamics of Proximod in healthy subjects. The main questions it arms to answer are:1. to evaluate the safety and tolerance of Proximod in healthy subjects after single or repeated doses.2. to learn the pharmacodynamics of Proximod in healthy subjects after single or repeated doses.3. to evaluation of the effect of food on the pharmacokinetics of Proximod in healthy subjects Participants will receive test tablets or placebo at the indicated date and collect blood samples., conditionsModule conditions: Rheumatoid Arthritis, designModule studyType: INTERVENTIONAL, phases: PHASE1, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: TREATMENT, maskingInfo masking: DOUBLE, whoMasked: PARTICIPANT, whoMasked: INVESTIGATOR, enrollmentInfo count: 134, type: ACTUAL, armsInterventionsModule interventions name: Proximod, interventions name: Placebo, outcomesModule primaryOutcomes measure: Peak plasma concentration (Cmax), primaryOutcomes measure: Time to peak plasma concentration (Tmax), primaryOutcomes measure: The lowest plasma concentration (Cmin), primaryOutcomes measure: Half-life (t1/2), primaryOutcomes measure: Number of adverse events and number of participants with adverse events, secondaryOutcomes measure: Lymphocyte count, secondaryOutcomes measure: Percentage of CD3+CD4+ and CD3+CD8+ T cells, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 50 Years, stdAges: ADULT, contactsLocationsModule locations facility: The first hospital of Jilin University, city: Changchun, state: Jilin, country: China, geoPoint lat: 43.88, lon: 125.32278, hasResults: False
protocolSection identificationModule nctId: NCT06361173, orgStudyIdInfo id: STUDY00004127, briefTitle: Spanish BMT4me Usability & Acceptability, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-06-01, primaryCompletionDateStruct date: 2026-05-01, completionDateStruct date: 2026-05-01, studyFirstPostDateStruct date: 2024-04-11, lastUpdatePostDateStruct date: 2024-04-11, sponsorCollaboratorsModule leadSponsor name: Nationwide Children's Hospital, class: OTHER, collaborators name: Columbia University, descriptionModule briefSummary: The objective of this project is to trans-create, conduct user testing of a previously developed and piloted mHealth app, and user acceptability with parents of children in the acute phase post-allogeneic hematopoietic stem cell transplant (HSCT). Nationwide Children's Hospital (NCH) will be the primary data collection site and Columbia University Irving Medical Center will be a secondary site., conditionsModule conditions: Bone Marrow Transplant, designModule studyType: OBSERVATIONAL, designInfo observationalModel: OTHER, timePerspective: CROSS_SECTIONAL, enrollmentInfo count: 30, type: ESTIMATED, armsInterventionsModule interventions name: BMT4me, outcomesModule primaryOutcomes measure: Assess app usability using the System Usability Scale (SUS), eligibilityModule sex: ALL, minimumAge: 0 Years, maximumAge: 17 Years, stdAges: CHILD, contactsLocationsModule locations facility: Columbia University Irving Medical Center, city: New York, state: New York, zip: 10027, country: United States, contacts name: Melissa Beauchemin, role: CONTACT, email: mmp2123@cumc.columbia.edu, geoPoint lat: 40.71427, lon: -74.00597, locations facility: Nationwide Children's Hospital, city: Columbus, state: Ohio, zip: 43215, country: United States, contacts name: Bianca Franklin, BS, role: CONTACT, contacts name: Micah Skeens, PhD, role: PRINCIPAL_INVESTIGATOR, geoPoint lat: 39.96118, lon: -82.99879, hasResults: False
protocolSection identificationModule nctId: NCT06361147, orgStudyIdInfo id: 3764/2-10-2019, briefTitle: Psychoeducation of Adult Siblings of ASD People (Autism Spectrum Disorder)., statusModule overallStatus: ACTIVE_NOT_RECRUITING, startDateStruct date: 2024-03-28, primaryCompletionDateStruct date: 2024-07, completionDateStruct date: 2024-10, studyFirstPostDateStruct date: 2024-04-11, lastUpdatePostDateStruct date: 2024-04-11, sponsorCollaboratorsModule leadSponsor name: Hellenic Mediterranean University, class: OTHER, descriptionModule briefSummary: The aim of this study is to apply a psychoeducational program in adult siblings of people with ASD as a means to provide knowledge related to the disorder and improving their quality of life.The psycho-educational program will be implemented in adult siblings of people with ASD and its effectiveness will be assessed.Participation in this program is expected to contribute in the improvement of the quality of life of the participants, their siblings with ASD and those related to them. No risk is identified., conditionsModule conditions: Autism Spectrum Disorder, conditions: Sibling Relations, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, interventionModelDescription: Interventional groups and Control groups, primaryPurpose: SUPPORTIVE_CARE, maskingInfo masking: SINGLE, whoMasked: PARTICIPANT, enrollmentInfo count: 88, type: ACTUAL, armsInterventionsModule interventions name: Cygnet program for ASD, outcomesModule primaryOutcomes measure: Psychoeducation effectiveness on siblings of ASD, primaryOutcomes measure: Psychoeducation effectiveness on the knowledge of ASD, primaryOutcomes measure: Psychoeducation effectiveness on siblings relationship, primaryOutcomes measure: Psychoeducation effectiveness on resilience of siblings of ASD, primaryOutcomes measure: Psychoeducation effectiveness on the well-being of siblings of ASD, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 60 Years, stdAges: ADULT, contactsLocationsModule locations facility: Hellenic Mediterranean University, city: Heraklion, state: Crete, zip: 82102, country: Greece, geoPoint lat: 35.32787, lon: 25.14341, hasResults: False
protocolSection identificationModule nctId: NCT06361134, orgStudyIdInfo id: 14574941-302,08,01-, briefTitle: Efficacy of Supporting SAFE Early Intervention, statusModule overallStatus: COMPLETED, startDateStruct date: 2021-01-15, primaryCompletionDateStruct date: 2022-05-15, completionDateStruct date: 2022-11-15, studyFirstPostDateStruct date: 2024-04-11, lastUpdatePostDateStruct date: 2024-04-11, sponsorCollaboratorsModule leadSponsor name: Gazi University, class: OTHER, descriptionModule briefSummary: Within the scope of the study, it was planned that risky babies would be treated with the SAFE early intervention approach for 10 weeks after they were discharged from the intensive care unit. Neurodevelopmental Treatment was applied to the control group. Sensory, motor and language development of the babies were evaluated before and after the intervention., conditionsModule conditions: Infant Development, conditions: Physiotherapy, conditions: Early Intervention, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: TREATMENT, maskingInfo masking: SINGLE, whoMasked: OUTCOMES_ASSESSOR, enrollmentInfo count: 26, type: ACTUAL, armsInterventionsModule interventions name: SAFE Early İntervention, interventions name: NDT based therapy, outcomesModule primaryOutcomes measure: Test of Infant Motor Profile, secondaryOutcomes measure: Bayley Scales of Infant and Toddler Development, Third Edition,, secondaryOutcomes measure: Infant/Toddler Sensory Profile 2, secondaryOutcomes measure: Infant/Toddler HOME Inventory, eligibilityModule sex: ALL, minimumAge: 1 Month, maximumAge: 3 Months, stdAges: CHILD, contactsLocationsModule locations facility: Erzurum Technical University, city: Erzurum, country: Turkey, geoPoint lat: 39.90861, lon: 41.27694, hasResults: False
protocolSection identificationModule nctId: NCT06361095, orgStudyIdInfo id: R01GABM, briefTitle: Confirmatory Efficacy Trial of Attention Bias Modification for Depression, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-05-01, primaryCompletionDateStruct date: 2028-03-01, completionDateStruct date: 2028-03-01, studyFirstPostDateStruct date: 2024-04-11, lastUpdatePostDateStruct date: 2024-04-16, sponsorCollaboratorsModule leadSponsor name: University of Texas at Austin, class: OTHER, collaborators name: Arcade Therapeutics, descriptionModule briefSummary: The goal of this clinical trial is to compare the efficacy of two related, but different ABM (Attention Biased Modification) treatments for depression in adults with elevated symptoms of depression. The main aims are:* Aim 1:examine whether gamified ABM leads to greater change in the primary and secondary outcomes than sham ABM* Aim 1: establish that gamified ABM is at least as effective as traditional ABM.* Aim 2: identify moderators of ABM efficacy and mechanisms responsible for its efficacy.* Aim 3: Identify the durability of ABM on depression symptoms during short-term follow-upParticipants will complete self-report questionnaires, complete eye-tracking tasks, and be clinically assessed through interviews by clinician researchers.If there is a comparison group: Researchers will compare sham, traditional, and gamified treatment groups to see if they moderate symptoms of depression., conditionsModule conditions: Depression, designModule studyType: INTERVENTIONAL, phases: EARLY_PHASE1, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: TREATMENT, maskingInfo masking: QUADRUPLE, whoMasked: PARTICIPANT, whoMasked: CARE_PROVIDER, whoMasked: INVESTIGATOR, whoMasked: OUTCOMES_ASSESSOR, enrollmentInfo count: 600, type: ESTIMATED, armsInterventionsModule interventions name: Traditional Attention Bias Modification, interventions name: Gamified Attention Bias Modification, interventions name: Sham Attention Bias Modification, outcomesModule primaryOutcomes measure: QIDS (Quick Inventory of Depression Symptoms) SR-16, secondaryOutcomes measure: Sheehan Disability Scale (SDS), secondaryOutcomes measure: Snaith-Hamilton Pleasure Scale (SHAPS), secondaryOutcomes measure: Hamilton Depression Rating Scale (HAM-D), secondaryOutcomes measure: Generalized Anxiety Disorder (GAD-7), secondaryOutcomes measure: Perseverative Thinking Questionnaire (PTQ), eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 70 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Institute for Mental Health Research, city: Austin, state: Texas, zip: 78705, country: United States, contacts name: Christopher G Beevers, PhD, role: CONTACT, email: beevers@utexas.edu, contacts role: CONTACT, email: beevers@utexas.edu, geoPoint lat: 30.26715, lon: -97.74306, documentSection largeDocumentModule largeDocs typeAbbrev: ICF, hasProtocol: False, hasSap: False, hasIcf: True, label: Informed Consent Form, date: 2024-04-05, uploadDate: 2024-04-08T12:13, filename: ICF_000.pdf, size: 143608, hasResults: False
protocolSection identificationModule nctId: NCT06361069, orgStudyIdInfo id: aslıakdeniz, briefTitle: Reducing Anxiety in Children Undergoing Day Surgery, statusModule overallStatus: COMPLETED, startDateStruct date: 2023-04-01, primaryCompletionDateStruct date: 2023-08-01, completionDateStruct date: 2024-01-01, studyFirstPostDateStruct date: 2024-04-11, lastUpdatePostDateStruct date: 2024-04-11, sponsorCollaboratorsModule leadSponsor name: Bilecik Seyh Edebali Universitesi, class: OTHER, descriptionModule briefSummary: Aim: This study was conducted to determine the efﬁcacy of finger puppets, distraction cards and kaleidoscope for reducing anxiety in children undergoing day surgery.Methods: The study was conducted using the "pre-post test unmatched group model", one of the quasi-experimental methods. The study was conducted between April 2023 and January 2024 with children aged 6-12 years who were admitted to the pediatric clinic of a hospital for day surgery. A total of 85 children (including 20 children in the control group, 22 children in the finger puppet intervention group, 21 children in the distraction cards intervention group, and 22 children in the kaleidoscope intervention group) who were hospitalized in the pediatric clinic between April 2023 and January 2024 and who met the inclusion criteria were included in the study. Descriptive statistics, Mann Whitney U test, Kruskal Wallis and regression analysis were used in the evaluation of the data., conditionsModule conditions: Anxiety, conditions: Child, Only, conditions: Surgery, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: NON_RANDOMIZED, interventionModel: PARALLEL, interventionModelDescription: The study was conducted using the "pre-post test unpaired group model", one of the quasi-experimental methods., primaryPurpose: SUPPORTIVE_CARE, maskingInfo masking: NONE, enrollmentInfo count: 85, type: ACTUAL, armsInterventionsModule interventions name: distraction cards, kaleidoscope and finger puppet, outcomesModule primaryOutcomes measure: Anxiety, eligibilityModule sex: ALL, minimumAge: 6 Years, maximumAge: 12 Years, stdAges: CHILD, contactsLocationsModule locations facility: Bilecik Şeyh Edebali University, city: Bilecik, country: Turkey, geoPoint lat: 40.14192, lon: 29.97932, hasResults: False